About Us EPD aims at applying brown adipocyte
induction technology
to the prevention and treatment of
obesity and diabetes.

About Us

EPD Co., Ltd. is developing its own pipeline in Drug Discovery and Development of EPS Creative Health Technology Group Limited (Hong Kong)’s healthcare business. It’s aiming for the prevention and treatment of obesity and diabetes using its brown adipocyte derivative technology. EPS’s strengths include its expertise and know-how in Japan and China, which it has cultivated over the years, and its access to China. Based on these strengths, we are working on a daily basis to realize the early commercialization of our pipeline.

Greetings from the President

EPD Co., Ltd.
Representative Director
Tomohiro Nakatani

Our company was founded with the aim of developing regenerative medicine and food products that can contribute to the weight reduction in overweight or obesity adults. We utilize technology invented in academia, which provides a new process capable of performing direct conversion of or induction from somatic cells to brown adipocytes. Brown adipose tissue is a fat tissue in the body that burns fat to generate heat, and there is a reported negative correlation between body mass index (BMI) and the thermogenic activity of brown adipose tissue in adults.

In Japan, the proportion of obese people (BMI ≥ 25 kg/m2) is 33.0% for males and 22.3% for females, with a significant increase observed in males from 2013 to 2019. According to the World Health Organization (WHO) criteria, the proportion of obese people in Japan (BMI ≥ 30 kg/m2) is 4.6%, the second lowest among 37 OECD member countries, after South Korea’s 4.3%. However, obesity is a major risk factor for many chronic diseases such as diabetes, cardiovascular diseases, and cancer. We believe that treating and preventing obesity can contribute to extending people’s healthy life expectancy.

Brown adipose tissue is present in various areas, such as between the shoulder blades, around the kidneys, above the clavicle, in the axillary region, and beside the spine. Brown adipose tissue between the shoulder blades is observed in newborns and infants but decreases with age and is not observed in adults. Our company aims to establish regenerative medicine technology by cultivating fibroblasts collected from the body, inducing them into brown adipocytes, and then transplanting them into the body.

In recent years, GLP-1 receptor agonists have gathered attention as a treatment for chronic weight management in obese or overweight adult patients. While these drugs are thought to induce a sense of fullness and suppress appetite, our technology aims to target the burning of fat and heat production within the body through the transplanted brown adipocytes. We hope that our approach will become a new option for the prevention and treatment of obesity.

Our company is advancing the development of this technology with a sense of urgency, with the initial goal of starting business in Japan.

Member referrals

Audit & Supervisory Corporate Officer

Contact Us

For more information,
please feel free to contact us from below.